Aligos Therapeutics, Inc. (ALGS) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 2.83M | 169K | 741K | 965K | 311K | 629K | 1.27M | 1.06M | 986K | 2.68M | 3.24M | 6.89M |
| Revenue Growth % | 809.97% | -73.13% | -41.61% | -9.05% | -68.46% | -76.54% | -60.82% | -84.59% | -63.79% | -24.2% | -21.12% | 86.46% |
| Cost of Goods Sold | 0 | 257K | 0 | 259K | 0 | 0 | 0 | 610K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 152.07% | - | 26.84% | - | - | - | 57.49% | - | - | - | - |
| Gross Profit | 2.83M | -88K | 741K | 706K | 311K | 629K | 1.27M | 451K | 986K | 2.68M | 3.24M | 6.89M |
| Gross Margin % | 100% | -52.07% | 100% | 73.16% | 100% | 100% | 100% | 42.51% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | 809.97% | -113.99% | -41.61% | 56.54% | -68.46% | -76.54% | -60.82% | -93.45% | -63.79% | -24.2% | -21.12% | 86.46% |
| Operating Expenses | 29.76M | 21.73M | 29.1M | 19.27M | 19.55M | 21.19M | 21.4M | 26.86M | 23.03M | 28.68M | 22.31M | 26.03M |
| OpEx % of Revenue | 1051.55% | 12855.62% | 3927.4% | 1997.2% | 6287.46% | 3369.16% | 1686.37% | 2532.05% | 2335.9% | 1069.68% | 688.79% | 377.97% |
| Selling, General & Admin | 6.41M | 4.69M | 5.17M | 5.56M | 5.05M | 5.16M | 4.63M | 5.77M | 6.67M | 6.42M | 6.44M | 9.25M |
| SG&A % of Revenue | 226.4% | 2773.96% | 697.03% | 575.75% | 1624.44% | 820.51% | 364.54% | 543.45% | 676.06% | 239.5% | 198.92% | 134.27% |
| Research & Development | 23.35M | 17.04M | 23.94M | 13.98M | 14.5M | 16.03M | 16.77M | 21.1M | 16.37M | 22.26M | 15.87M | 16.78M |
| R&D % of Revenue | 825.16% | 10081.66% | 3230.36% | 1448.29% | 4663.02% | 2548.65% | 1321.83% | 1988.6% | 1659.84% | 830.18% | 489.87% | 243.7% |
| Other Operating Expenses | 0 | 0 | 0 | -259K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -26.93M | -21.81M | -28.36M | -18.57M | -19.24M | -20.56M | -20.13M | -26.41M | -22.05M | -26M | -19.07M | -19.14M |
| Operating Margin % | -951.55% | -12907.69% | -3827.4% | -1924.04% | -6187.46% | -3269.16% | -1586.37% | -2489.54% | -2235.9% | -969.68% | -588.79% | -277.97% |
| Operating Income Growth % | -39.94% | -6.08% | -40.88% | 29.71% | 12.71% | 20.9% | -5.56% | -38% | 7.83% | -14.62% | -0.65% | 6.14% |
| EBITDA | -26.58M | -21.56M | -27.66M | -18.31M | -18.73M | -19.89M | -19.46M | -25.8M | -21.37M | -25.22M | -18.39M | -18.37M |
| EBITDA Margin % | -939.33% | -12755.62% | -3733.2% | -1897.2% | -6023.47% | -3162.48% | -1533.81% | -2432.05% | -2167.55% | -940.77% | -567.77% | -266.8% |
| EBITDA Growth % | -41.9% | -8.37% | -42.12% | 29.05% | 12.35% | 21.13% | -5.84% | -40.45% | 7.38% | -15.78% | -1.93% | 5.8% |
| D&A (Non-Cash Add-back) | 346K | 257K | 698K | 259K | 510K | 671K | 667K | 610K | 674K | 775K | 681K | 769K |
| EBIT | -26.93M | -21.81M | -31.48M | -15.68M | -19.24M | -20.56M | -20.13M | -26.41M | -22.05M | -26M | -19.07M | -19.14M |
| Net Interest Income | 811K | 548K | 378K | 396K | 842K | 314K | 457K | 319K | 580K | 1.59M | 1M | 955K |
| Interest Income | 811K | 548K | 378K | 396K | 842K | 314K | 457K | 319K | 580K | 1.59M | 1M | 955K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.21M | 1.96M | -3.12M | 2.89M | 62.37M | -61.56M | 963K | 31.66M | -12.79M | -1.93M | 1.06M | 1.11M |
| Pretax Income | -22.72M | -19.85M | -31.48M | -15.68M | 43.13M | -82.12M | -19.17M | 5.25M | -34.84M | -27.92M | -18.01M | -18.03M |
| Pretax Margin % | -802.93% | -11746.15% | -4248.45% | -1624.66% | 13868.49% | -13056.12% | -1510.48% | 494.82% | -3533.37% | -1041.48% | -556.1% | -261.89% |
| Income Tax | 317K | 30K | 56K | 185K | 43K | 27K | 91K | 189K | 24K | -30K | 29K | 757K |
| Effective Tax Rate % | -1.4% | -0.15% | -0.18% | -1.18% | 0.1% | -0.03% | -0.47% | 3.6% | -0.07% | 0.11% | -0.16% | -4.2% |
| Net Income | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M | -18.04M | -18.79M |
| Net Margin % | -814.13% | -11763.91% | -4256.01% | -1643.83% | 13854.66% | -13060.41% | -1517.65% | 477% | -3535.8% | -1040.36% | -556.99% | -272.89% |
| Net Income Growth % | -153.47% | 75.8% | -63.75% | -413.44% | 223.59% | -194.53% | -6.75% | 126.93% | -51.88% | -27.44% | 3.11% | 5.69% |
| Net Income (Continuing) | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M | -18.04M | -18.79M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.21 | -1.91 | -3.04 | -1.53 | -2.11 | -13.08 | -3.07 | 0.81 | -2.24 | -1.12 | -0.41 | -0.43 |
| EPS Growth % | -4.74% | 85.4% | 0.98% | -288.89% | 5.8% | -1067.86% | -648.78% | 288.37% | -322.64% | -119.61% | 6.82% | 8.51% |
| EPS (Basic) | -2.21 | -1.91 | -3.04 | -1.53 | 5.12 | -13.08 | -3.07 | 0.81 | -2.24 | -1.12 | -0.41 | -0.43 |
| Diluted Shares Outstanding | 10.4M | 10.38M | 10.37M | 10.35M | 8.71M | 6.28M | 6.27M | 6.27M | 15.57M | 24.87M | 43.5M | 43.22M |
| Basic Shares Outstanding | 10.4M | 10.38M | 10.37M | 10.35M | 8.41M | 6.28M | 6.27M | 6.26M | 15.57M | 24.87M | 43.5M | 43.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |